BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Cystadenoma, Serous
  • Early Detection of Cancer
  • Mutation, Missense
  • Ovarian Neoplasms
  • Proto-Oncogene Proteins B-raf

abstract

  • V600E BRAF mutations were present in 35% of patients who had SB/LGS ovarian cancers. The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis. The authors concluded that patients with SB/LGS ovarian cancer who require systemic therapy are unlikely to have BRAF mutant tumors.

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3961140

Digital Object Identifier (DOI)

  • 10.1002/cncr.27782

PubMed ID

  • 22930283

Additional Document Info

start page

  • 548

end page

  • 54

volume

  • 119

number

  • 3